The anticoagulant reversal drug market in North America is expected to grow from US$ 414.7 million in 2019 to US$ 1,037.9 million by 2027; it is estimated to grow at a CAGR of 12.8% from 2019 to 2027.
The US, Canada, and Mexico are major economies in North America. Oral anticoagulants are widely used and are highly effective in preventing thromboembolism among AFib patients. However, the use of anticoagulants may lead to bleeding in AFib patients; thus, anticoagulant reversal drugs are used to prevent bleeding. As per the Centers for Disease Control and Prevention (CDC), in 2018, in the US, AFib was mentioned on around 175,326 death certificates and was the primary cause of death in about 25,845 of those deaths. Additionally, it has also anticipated that 12.1 million people in the US will have AFib by 2030.
According to the report "Beyond the Burden: The Impact of Atrial Fibrillation in Asia Pacific," from Biosense Webster (part of Johnson & Johnson Medical Devices Companies), atrial fibrillation is projected to affect around 72 million people by 2050. Thus, such high prevalence of atrial fibrillation is likely to favor the growth of the market.
With the new features and technologies, vendors can attract new customers and expand their footprints in emerging markets. This factor is likely to drive the anticoagulant reversal drugs market. The North America anticoagulant reversal drugs market is expected to grow at a good CAGR during the forecast period.
- This FREE sample will include data analysis, ranging from market trends to estimates and forecasts.
North America Anticoagulant Reversal Drug Market Segmentation
By Product
- Prothrombin Complex Concentrates
- Vitamin K
- Protamine
- Tranexamic Acid
- Idarucizumab
- AndeXXa
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Others
By Country
North America
- US
- Canada
- Mexico
Companies Mentioned
- Boehringer Ingelheim International GmbH
- Pfizer Inc
- Octapharma AG
- AMAG PHARMACEUTICALS, INC.
- Fresenius Kabi AG
- Alexion Pharmaceuticals, Inc. (Portola Pharmaceuticals)
- CSL Limited
- Grifols, S.A.
North America Anticoagulant Reversal Drug Report Scope
| Report Attribute | Details |
|---|---|
| Market size in 2019 | US$ 414.7 Million |
| Market Size by 2027 | US$ 1,037.9 Million |
| Global CAGR (2019 - 2027) | 12.8% |
| Historical Data | 2017-2018 |
| Forecast period | 2020-2027 |
| Segments Covered |
By Product
|
| Regions and Countries Covered | North America
|
| Market leaders and key company profiles |
- Historical Analysis (2 Years), Base Year, Forecast (7 Years) with CAGR
- PEST and SWOT Analysis
- Market Size Value / Volume - Global, Regional, Country
- Industry and Competitive Landscape
- Excel Dataset
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
Product, End User
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
US, Canada
Trends and growth analysis reports related to Life Sciences : READ MORE..
- Boehringer Ingelheim International GmbH
- Pfizer Inc
- Octapharma AG
- AMAG PHARMACEUTICALS, INC.
- Fresenius Kabi AG
- Alexion Pharmaceuticals, Inc. (Portola Pharmaceuticals)
- CSL Limited
- Grifols, S.A.
Get Free Sample For